FDA expands approval of Amgen's bone drug Prolia

09/19/2011 | HealthDay News · Boulder County Business Report (Colo.)

The FDA approved Amgen's Prolia to prevent bone fractures in patients with breast or prostate cancer who are undergoing certain hormone therapies. Prolia was originally indicated for postmenopausal women at high risk of osteoporotic fracture.

View Full Article in:

HealthDay News · Boulder County Business Report (Colo.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC